Skip to main content

Table 2 Individual SpA subject characteristics

From: Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles

Subject

Dataset

Gender

Race

SpA Likelihood ratio

Medications

1

1

M

Asian

4073

None (Etanercept withdrawn for 2 months)

2*

1

M

Caucasian

204

Simvastatin, cyclobenzaprine, aspirin, indomethacin, atenolol, lansoprazole, hydrocodone

3

1

M

Caucasian

204

_

4

1

M

Caucasian

4073

_

5

1

M

Caucasian

934

_

6

1

M

Asian

204

_

7

1

M

Caucasian

4073

Metformin, glipizide, atorvastatin, lisinopril, nifedipine, Lantus insulin, Novo Log, sulfasalazine, indomethacin

8

1

M

Caucasian

558

Ibuprofen

9

1

F

Caucasian

11383

Piroxicam, indomethacin

10

1

F

Caucasian

7115

Rofecoxib

11

1

M

Caucasian

255

Acetaminophen, ramipril, omeprazole, aspirin, atorvastatin

12

2

M

Caucasian

4073

Insulin, nifedipine, glipizide, lisinopril, metformin, Vicodin, Flexeril, indomethacin, sulfasalazine

13

2

F

Caucasian

1039

Celecoxib, trazodone, venlafaxine, ranitidine

14

2

F

Caucasian

204

Tobramycin

15

2

F

Asian

4073

Alendronate

16

2

M

Asian

204

_

17

2

M

Caucasian

20774

Phenylbutazone

18

2

M

Caucasian

2308

Alendronate sodium

  1. *coexistent ulcerative colitis. F = female; M = male; SpA = axial spondyloarthropathy.